After speaking with a clinician who specializes in seizures and hosting meetings with the management of GW Pharmaceuticals, Piper Jaffray analyst Joshua Schimmer says his confidence in the company's ability to successfully navigate clinical, regulatory and commercial challenges for Epidiolex, and for shares to "appreciate considerably" as a result, has never been higher. The Phase 3 Epidiolex data in the first half of 2016 "marks an important inflection point" for GW, Schimmer tells investors in a research note. He continues to view GW as top midcap pick and reiterates an Overweight rating on the name with a $147 price target. The stock closed yesterday up $1.00 to $86.28.